Xtant Medical (NYSEAMERICAN:XTNT) Releases Earnings Results, Misses Expectations By $0.05 EPS

Xtant Medical (NYSEAMERICAN:XTNT) issued its quarterly earnings results on Tuesday. The medical device company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.05), FiscalAI reports. The business had revenue of $23.03 million during the quarter, compared to analyst estimates of $24.88 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Here are the key takeaways from Xtant Medical’s conference call:

• Revenue and guidance declined: Q2 revenue fell to $23.0 million from $24.8 million on a pro forma basis, primarily due to weakness in legacy orthobiologics and amnio products. Xtant reduced full-year revenue guidance to $99 million–$103 million from $101 million–$105 million.
• Profitability weakened materially: Gross margin fell to 57.9% from 68.6%, while the company reported a $9.4 million net loss and a $2.7 million adjusted EBITDA loss, partly reflecting the $5 million Dilon fee, lower production efficiency, and inventory charges.
• HEMOBLAST® integration is progressing: The company recognized approximately $1.5 million of Q2 HEMOBLAST® revenue and expects transactional volume to exceed $1 million per month on a gross basis, with substantially all future sales expected to flow through Xtant’s contracts and distribution network.
• Expanded commercial reach and new products support future growth: Xtant integrated 17 Dilon salespeople and expanded its broader commercial team to more than 25 representatives, while reporting strong early traction for Trivium™ Shaped. Management expects these investments and cross-selling opportunities to accelerate biologics growth in the second half of 2026.

Xtant Medical Stock Down 21.5%

Shares of XTNT traded down $0.10 during midday trading on Tuesday, hitting $0.35. The company had a trading volume of 292,357 shares, compared to its average volume of 136,219. The company has a quick ratio of 1.64, a current ratio of 3.34 and a debt-to-equity ratio of 0.17. Xtant Medical has a 52 week low of $0.34 and a 52 week high of $0.95. The company’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.51. The stock has a market cap of $49.09 million, a price-to-earnings ratio of 35.04 and a beta of -0.13.

Analyst Upgrades and Downgrades

Separately, BTIG Research restated a “buy” rating and set a $1.00 price objective on shares of Xtant Medical in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $1.00.

Institutional Trading of Xtant Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wiregrass Investment Management LLC bought a new stake in shares of Xtant Medical during the 4th quarter valued at about $81,000. Renaissance Technologies LLC lifted its position in Xtant Medical by 28.8% in the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after purchasing an additional 205,945 shares during the last quarter. Vanguard Group Inc. grew its holdings in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares in the last quarter. Mink Brook Asset Management LLC raised its stake in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of Xtant Medical by 500.3% during the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after acquiring an additional 57,000,000 shares during the period. 69.33% of the stock is owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.